Table 2: Ongoing trials comparing dexamethasone with methylprednisolone in COVID-19.
|
Study |
Country |
Sample |
Treatment arms |
Primary outcome |
Current status |
|
NCT04603729 |
Pakistan |
COVID 19 adults SpO2 ≤ 94%, requiring supplemental oxygen |
IV dexamethasone 8 mg daily x 5 days vs. IV MTP 1 mg/kg daily x 5 days |
Temperature, oxygen saturation, CRP, mortality and ICU stay |
Completed |
|
NCT04499313 |
Bangladesh |
COVID-19 adults with ARDS |
IV dexamethasone 20 mg daily with taper vs. IV MTP 0.5 mg/kg daily |
30-day mortality, clinical improvement |
Recruiting |
|
NCT04636671 |
Italy |
COVID-19 adults SpO2 ≤ 90%, requiring supplemental oxygen |
IV dexamethasone 6 mg daily x 10 days vs. IV MTP 160 mg on day 1 followed by 80 mg daily for 7 days |
28-day survival |
Recruiting |
|
NCT04780581 |
Spain |
COVID-19 adults SpO2 ≤ 93%, requiring supplemental oxygen |
IV dexamethasone 6 mg daily x 10 days vs. IV MTP 250 mg daily x days |
28-day mortality |
Recruiting |
MTP: Methylprednisolone; CRP: C-Reactive Protein; ICU: Intensive Care Unit; SpO2: Oxygen Saturation; ARDS: Acute Respiratory Distress Syndrome